[1] |
Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study[J]. Br J Cancer, 2001, 85(1):41-45.
doi: 10.1054/bjoc.2001.1699
URL
|
[2] |
Zhang W, Jiang SP and Huang L. Dermatomyositis and malignancy: Aretrospective study of 115 cases[J]. Eur Rev Med Pharmacol Sci, 2009, 13(2):77-80.
|
[3] |
Azuma K, Yamada H, Ohkubo M, et al. Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis[J]. Mod Rheumatol, 2011, 21(2):178-183.
doi: 10.3109/s10165-010-0362-y
URL
|
[4] |
Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: A population-based study[J]. Lancet, 2001, 357(9250):96-100.
pmid: 11197446
|
[5] |
Chen D, Yuan S, Wu X, et al. Incidence and predictive factors for malignancies with dermatomyositis: A cohort from southern China[J]. Clin Exp Rheumatol, 2014, 32(5):615-621.
|
[6] |
Leatham H, Schadt C, Chisolm S, et al. Evidence supports blind screening for internal malignancy in dermatomyositis: Data from 2 large US dermatology cohorts[J]. Medicine (Baltimore), 2018, 97(2):e9639.
doi: 10.1097/MD.0000000000009639
URL
|
[7] |
Wang J, Guo G, Chen G, et al. Meta-analysis of the association of dermatomyositis and polymyositis with cancer[J]. Br J Dermatol, 2013, 169(4):838-847.
doi: 10.1111/bjd.12564
pmid: 23909921
|
[8] |
Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kdprotein is associated with dermatomyositis[J]. Arthritis Rheum, 2006, 54(11):3682-3689.
doi: 10.1002/art.22164
URL
|
[9] |
Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with 155 and 140kDa nuclear proteins in patients with dermatomyositis: An association with malignancy[J]. Rheumatology (Oxford), 2007, 46(1):25-28.
doi: 10.1093/rheumatology/kel161
URL
|
[10] |
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts)[J]. N Engl J Med, 1975, 292(7):344-347.
doi: 10.1056/NEJM197502132920706
URL
|
[11] |
Sontheimer RD, Miyagawa S. Potentially fatal interstitial lung disease can occur in clinically amyopathic dermatomyositis[J]. J Am Acad Dermatol, 2003, 48(5):797-798.
pmid: 12734516
|
[12] |
Chen DY, Chen YM, Lan JL, et al. Polymyositis/dermatomyositis and nasopharyngeal carcinoma: The Epstein-Barr virus connection?[J]. J Clin Virol, 2010, 49(4):290-295.
doi: 10.1016/j.jcv.2010.08.015
URL
|
[13] |
Ogawa-Momohara M, Muro Y, Mitsuma T, et al. Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients[J]. Clin Exp Rheumatol, 2018, 36(6):990-995.
pmid: 29745874
|
[14] |
Selva-O’Callaghan A, Trallero-Araguás E, Grau-Junyent JM, et al. Malignancy and myositis: Novel autoantibodies and new insights[J]. Curr Opin Rheumatol, 2010, 22(6):627-632.
doi: 10.1097/BOR.0b013e32833f1075
pmid: 20827204
|
[15] |
Ueda-Hayakawa I, Hamaguchi Y, Okiyama N, et al. Autoantibody to transcriptional intermediary factor-1β as a myositis-specific antibody: Clinical correlation with clinically amyopathic dermatomyositis or dermatomyositis with mild myopathy[J]. Br J Dermatol, 2019, 180(4):881-887.
doi: 10.1111/bjd.17098
pmid: 30120913
|
[16] |
Ueki M, Kobayashi I, Takezaki S, et al. Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies[J]. Mod Rheumatol, 2019, 29(2):351-356.
doi: 10.1080/14397595.2018.1452353
URL
|
[17] |
Hamaguchi Y, Kuwana M, Hoshino K, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult-Japanese patients with dermatomyositis: A multicenter cross-sectional study[J]. Arch Dermatol, 2011, 147(4):391-398.
doi: 10.1001/archdermatol.2011.52
pmid: 21482889
|
[18] |
Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: Their clinical and pathogenic significance in disease expression[J]. Rheumatology(Oxford), 2009, 48(6):607-612.
doi: 10.1093/rheumatology/kep078
URL
|